Alexandros Makriyannis Selected Research

AM 6701

10/2012

Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexandros Makriyannis Research Topics

Disease

27	Pain (Aches) 10/2021 - 09/2001
15	Inflammation (Inflammations) 01/2022 - 10/2003
14	Hyperalgesia 01/2022 - 10/2003
12	Obesity 12/2020 - 10/2007
11	Neuralgia (Stump Neuralgia) 01/2022 - 09/2003
11	Hypothermia 10/2018 - 09/2001
8	Neoplasms (Cancer) 01/2022 - 12/2016
8	Substance-Related Disorders (Drug Abuse) 01/2021 - 10/2007
7	Tobacco Use Disorder (Nicotine Dependence) 01/2019 - 01/2012
6	Hypersensitivity (Allergy) 01/2021 - 09/2003
5	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 11/2008
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2021 - 03/2008
5	Catalepsy 08/2015 - 09/2001
4	Body Weight (Weight, Body) 10/2020 - 12/2007
4	Vomiting 01/2020 - 07/2007
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 04/2006
4	Weight Loss (Weight Reduction) 12/2016 - 08/2006
4	Nausea 01/2016 - 07/2007
3	Fibrosis (Cirrhosis) 02/2021 - 03/2012
3	Insulin Resistance 10/2020 - 08/2010
3	Multiple Sclerosis 01/2018 - 07/2005
3	Seizures (Absence Seizure) 09/2017 - 09/2007
3	Colitis 02/2015 - 11/2009
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2015 - 01/2006
2	Respiratory Insufficiency (Respiratory Failure) 10/2022 - 10/2021
2	Carcinogenesis 01/2022 - 02/2019
2	Neuroinflammatory Diseases 10/2021 - 01/2021
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 10/2011
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020 - 01/2019
2	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 11/2019 - 10/2018
2	Abdominal Pain (Pain, Abdominal) 11/2019 - 10/2018
2	Glaucoma 01/2019 - 07/2005
2	Hyperphagia (Overeating) 01/2019 - 10/2011
2	Marijuana Abuse (Cannabis Abuse) 01/2016 - 11/2002
2	Dementia (Dementias) 01/2014 - 11/2008
2	Weight Gain 10/2011 - 12/2007
2	Overweight 03/2009 - 03/2008
2	Immune System Diseases (Immune Disorders) 11/2008 - 03/2008

Drug/Important Bio-Agent (IBA)

39	CannabinoidsIBA 10/2022 - 09/2001
24	EndocannabinoidsIBA 01/2021 - 03/2003
15	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 02/2021 - 07/2005
12	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 12/2002
12	AM 1241IBA 01/2022 - 09/2001
11	Pharmaceutical PreparationsIBA 01/2022 - 11/2003
11	CB2 Cannabinoid ReceptorIBA 01/2022 - 02/2003
10	RimonabantIBA 03/2019 - 02/2004
9	3- (1,1- dimethyl- heptyl)- 1- hydroxy- 9- methoxy- benzo(c)chromen- 6- oneIBA 01/2022 - 06/2011
9	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 11/2008
9	AM4113IBA 02/2021 - 12/2007
8	N-acylethanolaminesIBA 01/2022 - 02/2015
8	anandamide (arachidonylethanolamide)IBA 01/2019 - 08/2002
7	Analgesics (Analgesic Drugs)IBA 10/2018 - 02/2003
6	Morphine (MS Contin)FDA LinkGeneric 10/2022 - 02/2013
6	Opioid Analgesics (Opioids)IBA 10/2022 - 02/2013
6	AcidsIBA 01/2022 - 02/2015
6	amidaseIBA 01/2022 - 02/2015
6	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 01/2021 - 08/2002
6	Nicotine FDA Link 01/2020 - 04/2012
5	EnzymesIBA 01/2021 - 03/2012
5	Proteins (Proteins, Gene)FDA Link 12/2020 - 08/2002
5	LigandsIBA 04/2016 - 03/2008
4	palmidrolIBA 01/2021 - 02/2015
4	LipidsIBA 01/2021 - 08/2010
4	Dronabinol (THC)FDA LinkGeneric 01/2019 - 12/2012
4	Cannabinoid Receptor AgonistsIBA 03/2012 - 02/2003
3	Monoacylglycerol LipasesIBA 01/2022 - 03/2012
3	methanandamideIBA 10/2021 - 02/2013
3	AM6545IBA 02/2021 - 10/2017
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 02/2015
3	CytokinesIBA 12/2020 - 03/2012
3	Glycerol (Glycerine)FDA LinkGeneric 01/2019 - 10/2012
3	N-(4-hydroxyphenyl)arachidonylamide (AM404)IBA 01/2016 - 03/2003
3	3- (1- hexylcyclobut- 1- yl)- 6a,7,8,9,10,10a- hexahydro- 6,6- dimethyl- 6H- dibenzo(b,d)pyran- 1,9 diolIBA 08/2015 - 03/2012
3	AM 251 (AM251)IBA 04/2014 - 12/2007
3	Glycoproteins (Glycoprotein)IBA 01/2014 - 11/2008
3	9- (hydroxymethyl)- 3- (1- adamantyl)hexahydrocannabinolIBA 08/2013 - 01/2013
2	MonoglyceridesIBA 09/2021 - 01/2016
2	Fatty Acids (Saturated Fatty Acids)IBA 09/2021 - 01/2013
2	AlbuminsIBA 02/2021 - 10/2017
2	Interleukin-10 (Interleukin 10)IBA 12/2020 - 03/2012
2	Serotonin (5 Hydroxytryptamine)IBA 11/2019 - 10/2018
2	AM9405IBA 11/2019 - 10/2018
2	N- pyridazin- 3- yl- 4- (3- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)benzylidene)piperidine- 1- carboxamideIBA 01/2019 - 01/2019
2	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 02/2013
2	Therapeutic UsesIBA 12/2018 - 10/2011
2	Ethanol (Ethyl Alcohol)IBA 01/2018 - 11/2008
2	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2014 - 02/2013
2	iodopravadoline (AM 630)IBA 04/2014 - 11/2009
2	Sulfonic AcidsIBA 01/2014 - 11/2009
2	pyrazoleIBA 02/2013 - 02/2004
2	Mesylates (Mesylate)IBA 02/2013 - 01/2013
2	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)IBA 01/2013 - 08/2006
2	Messenger RNA (mRNA)IBA 03/2012 - 11/2009
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2011 - 11/2008
2	BenzopyransIBA 11/2008 - 10/2006
2	Capsaicin (Zostrix)FDA Link 02/2004 - 10/2003

Therapy/Procedure

9	Therapeutics 10/2022 - 09/2003
8	Drug Therapy (Chemotherapy) 01/2022 - 03/2008
7	Analgesia 10/2021 - 05/2005
2	Ligation 01/2019 - 09/2003